Relmada Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Relmada Therapeutics

23/03/2023 21:01

* Relmada Therapeutics Inc  RLMD.OQ  reported a quarterly
adjusted
loss of $1.41​​ per share for the quarter ended in December. The
mean expectation of six analysts for the quarter was for a loss
of $1.33 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Relmada Therapeutics Inc's reported EPS for the quarter
was a
loss of $1.41​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Relmada Therapeutics Inc shares had fallen by 33.0% this
quarter.
    * The company reported a quarterly loss of $42.06 million.
    * Wall Street's median 12-month price target for Relmada
Therapeutics Inc is $8.25 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 23 at 09:00 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -1.33          -1.41          Missed
 Sep. 30 2022      -1.45          -1.31          Beat
 Jun. 30 2022      -1.27          -1.33          Missed
 Mar. 31 2022      -1.27          -1.40          Missed